Andrew Campbell, MD
Director, Comprehensive Sickle Cell Disease Program
Children’s National Hospital, Washington, DC
Associate Professor, Associate Professor of Pediatrics at George Washington University School of Medicine and Health Sciences

Dr. Campbell is a graduate of Morehouse College and Case Western Reserve School of Medicine.  He completed his pediatric residency training at the Harvard affiliated Massachusetts General Hospital; this was followed by a Pediatric Hematology/Oncology Fellowship at Northwestern University - Lurie’s Children’s Hospital. Currently, he is the Global Health Research Lead and Director of the Comprehensive Sickle Cell Disease (SCD) Program at Children’s National Hospital (CNH) in Washington, DC. Dr. Campbell is an Associate Professor of Pediatrics at George Washington University School of Medicine and Health Sciences, Washington, DC.  As an international expert, he has lectured regionally, nationally, and globally on issues related to the care and healthcare system approach to patients and families dealing with the effects of SCD. His research spans translational, population health, environmental and health outcomes research including publishing over 90 papers in peer reviewed journals mostly related to sickle cell disease research. He was an invited speaker at the Science Summit at the United Nations General Assembly (UNGA) on "Sickle Cell Disease: Gene Therapy to Improve Health and Cure Disease" and “Global Partnership for Sickle Cell Disease” in 2023 and 2024. Recently, in September 2024, he was a featured speaker at HHS’s first-ever Sickle Cell Disease Summit: "Empowered and Thriving SCD Warriors and Communities.". He has served on the Steering Committee for the Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) in London for the past 5 years.  Recently he was a featured speaker at the 2025 5th Global  Congress  on Sickle Cell Disease in Abuja, Nigeria delivering 2 invited lectures, including a Plenary Session platform presentation. He has participated in numerous advocacy efforts for SCD patients and their families which included assisting with Sickle Cell Treatment Centers Act Legislation, assisting the American Society of Gene & Cell Therapy on Sickle Cell Disease legislation on Capitol Hill, and other Congressional Briefings on Sickle Cell Disease. Dr. Campbell was the Principal Investigator of the American Society of Hematology Research Collaborative, “Washington DC, Maryland, Virginia (DMV) Sickle Cell Clinical Trials Network 2021-2025. He has also focused his research on the clinical complexity of Sickle Cell Disease (SCD) in different populations through a multinational international consortium (CASiRe - Consortium for the Advancement of Sickle Cell Disease Research) including participants from Ghana, Italy, United Kingdom, and the United States. Other international work includes being a member of the Sickle in Africa Research Consortia, where he contributes to the SCD Ontology working group.